Abstract Title

Evidence for improved motor function by ceftriaxone despite striatal tyrosine hydroxylase loss following nigrostriatal lesion

Presenter Name

Ella A. Kasanga

RAD Assignment Number

2001

Abstract

Purpose: The beta-lactam antibiotic, ceftriaxone, attenuates tyrosine hydroxylase (TH) loss in striatum in rodent Parkinson’s disease (PD) models when given early after nigrostriatal lesion. This protection may be related to the well-known properties of ceftriaxone to increase expression of the glutamate transporter, GLT-1, which increases glutamate uptake. Ser19 TH phosphorylation, which is modulated by glutamate and Ca2+-influx, increases in proportion to TH loss following nigrostriatal lesion and may predispose TH to premature degradation via the ubiquitin-proteasome pathway. Here we evaluated if ceftriaxone could partially restore striatal TH loss, concomitant with a decrease in motor impairment, when administered 1 week after lesion induction.

Methods: The ability of ceftriaxone to decrease motor impairment was evaluated after evidence of motor impairment by evaluation of forepaw adjustment steps (FAS) and open-field locomotor activity. Ceftriaxone (200 mg/kg, i.p.) was given intermittently on days 7-13, 21-27, and 35-38 post-lesion. Motor function 7 days after lesion induction was used as a baseline to evaluate if ceftriaxone could reduce motor impairment out to 40 days post-lesion.

Results: There was a significant increase in FAS taken, with an overall 45% increase in mean FAS post-lesion compared to the day 7 baseline. Locomotor activity (ambulatory count and total distance) increased at the end of the study (38 days post-lesion) against the day 7 baseline following ceftriaxone. >90% striatal TH protein loss was evident regardless of whether the rats received ceftriaxone or saline injection. However, in the substantia nigra, there was a significant increase in TH expression in the side contralateral to lesion in the ceftriaxone group.

Conclusion: Taken together, these results suggest that ceftriaxone-mediated protection against locomotor decline, after the establishment of a nigrostriatal lesion, may be independent of any preservation or possible restoration of striatal TH.

Is your abstract for competition or not for competition?

Competition

Research Area

Pharmacology

Presentation Type

Poster

This document is currently not available here.

Share

COinS
 

Evidence for improved motor function by ceftriaxone despite striatal tyrosine hydroxylase loss following nigrostriatal lesion

Purpose: The beta-lactam antibiotic, ceftriaxone, attenuates tyrosine hydroxylase (TH) loss in striatum in rodent Parkinson’s disease (PD) models when given early after nigrostriatal lesion. This protection may be related to the well-known properties of ceftriaxone to increase expression of the glutamate transporter, GLT-1, which increases glutamate uptake. Ser19 TH phosphorylation, which is modulated by glutamate and Ca2+-influx, increases in proportion to TH loss following nigrostriatal lesion and may predispose TH to premature degradation via the ubiquitin-proteasome pathway. Here we evaluated if ceftriaxone could partially restore striatal TH loss, concomitant with a decrease in motor impairment, when administered 1 week after lesion induction.

Methods: The ability of ceftriaxone to decrease motor impairment was evaluated after evidence of motor impairment by evaluation of forepaw adjustment steps (FAS) and open-field locomotor activity. Ceftriaxone (200 mg/kg, i.p.) was given intermittently on days 7-13, 21-27, and 35-38 post-lesion. Motor function 7 days after lesion induction was used as a baseline to evaluate if ceftriaxone could reduce motor impairment out to 40 days post-lesion.

Results: There was a significant increase in FAS taken, with an overall 45% increase in mean FAS post-lesion compared to the day 7 baseline. Locomotor activity (ambulatory count and total distance) increased at the end of the study (38 days post-lesion) against the day 7 baseline following ceftriaxone. >90% striatal TH protein loss was evident regardless of whether the rats received ceftriaxone or saline injection. However, in the substantia nigra, there was a significant increase in TH expression in the side contralateral to lesion in the ceftriaxone group.

Conclusion: Taken together, these results suggest that ceftriaxone-mediated protection against locomotor decline, after the establishment of a nigrostriatal lesion, may be independent of any preservation or possible restoration of striatal TH.